Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
Open Access
- 20 April 2010
- Vol. 116 (9), 2258-2265
- https://doi.org/10.1002/cncr.25089
Abstract
BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents. METHODS: Records of patients with desmoid tumors who were treated with chemotherapy at the study institution were reviewed. The activity of nonsteroidal anti–inflammatory drugs was not addressed. Patients without measurable disease and those receiving therapy could not be documented, and those receiving prophylactic therapy were excluded. RESULTS: A total of 68 patients received 157 lines of therapy. At the time of last follow–up, 9 patients had died, 7 of progressive disease. The cohort was 62% female, with a median age of 32.5 years. Approximately 32% of the patients had Gardner syndrome. The median follow‐up was 63 months, and patients received a median of 2 lines of therapy. An intra‐abdominal primary tumor location was the most common (44%). The greatest Response Evaluation Criteria in Solid Tumors (RECIST) response rate was observed with anthracyclines and hormonal therapy and the lowest response was noted with single‐agent dacarbazine/temozolomide or tyrosine kinase inhibitors, principally imatinib. On multivariate analysis, macroscopic nodular morphology and the presence of Gardner syndrome were the only tumor factors found to be associated with a greater time to disease progression. CONCLUSIONS: Compared with other agents, antiestrogens and anthracycline‐containing regimens appear to be associated with a higher radiological response rate against desmoid tumors. Systemic therapy can be successful in patients with desmoid tumors, and is a viable option in lieu of morbid or disabling surgery. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 23 references indexed in Scilit:
- Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid TumorsThe American Journal of Pathology, 2008
- Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patientsEuropean Journal of Surgical Oncology, 2008
- Optimizing Treatment of Desmoid TumorsJournal of Clinical Oncology, 2007
- Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)Journal of Clinical Oncology, 2006
- Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous PolyposisJournal of Clinical Oncology, 2006
- Combination chemotherapy for desmoid tumorsCancer, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)Oncogene, 1999
- Desmoid tumours complicating familial adenomatous polyposisBritish Journal of Surgery, 1999
- Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444Human Molecular Genetics, 1995